

Prediction driven functional annotation of hypothetical proteins in the major facilitator superfamily of *S. aureus* NCTC 8325

Jessica Marklevitz¹, Laura K. Harris^{1*}

¹Department of Science, Davenport University, 200 S. Grand Ave, Lansing, MI, 48933 United States of America *Corresponding author: laura.harris@davenport.edu

Received June 26, 2016; Revised July 10, 2016; Accepted July 11, 2016; Published July 26, 2016

Abstract:

Antibiotic resistance *Staphylococcus aureus* strains cause several life threatening infections. New drug treatment options are needed, but are slow to develop because 50% of the *S. aureus* genome is hypothetical. The goal of this is to aid in the annotation of the *S. aureus* NCTC 8325 genome by identifying hypothetical proteins related to the Major Facilitator Superfamily (MFS). The MFS is a broad protein group with members involved in drug efflux mechanisms causing resistance. To do this, sequences for three MFS proteins with x-ray crystal structures in *E. coli* were PSI-BLASTed against the *S. aureus* NCTC 8325 genome to identify homologs. Eleven identified hypothetical protein homologs underwent BLASTP against the non-redundant NCBI database to fit homologs specific to each hypothetical protein. ExPASy characterized the physiochemical features, CDD-BLAST and Pfam identified domains, and the SOSUI server defined transmembrane helices of each hypothetical protein. Based on size (300 – 700 amino acids), number of transmembrane helices (>7), CD06174 and MFS domains in CDD-BLAST and Pfam, respectively, and close relation to well-defined homologs, SAOUHSC_00058, SAOUHSC_00078, SAOUHSC_00952, SAOUHSC_02435, SAOUHSC_02752, and ABD31642.1 are members of the MFS. Further multiple-alignment and phylogeny analyses show SAOUHSC_00058 to be a quinolone resistance protein (NorB), SAOUHSC_00058 a siderophore biosynthesis protein (SbnD), SAOUHSC_00952 a glycolipid permease (LtaA), SAOUHSC_02435 a macrolide MFS transporter, SAOUHSC_02752 a chloramphenicol resistance (DHA1), and ABD31642.1 is a Bcr/CflA family drug resistance efflux transporter. These findings provide better annotation for the existing genome, and identify proteins related to antibiotic resistance in *S. aureus* NCTC 8325.

Background:

Staphylococcus aureus is an opportunistic pathogen responsible for a wide variety of infections including superficial skin and surgical wound infections, toxic shock syndrome, and bacteremia [1]. Most are nosocomial infections, though there are increases in community acquired (CA) Methicillin-resistant *Staphylococcus aureus* (MRSA) infections, particularly among immunocompromised patients. Other health issues related to internalized infections are heart and lung diseases such as endocarditis and necrotizing pneumonia found in younger community populations rather than remaining solely a hospital acquired infection. Deaths from *S. aureus* caused heart and lung infections are reported [2]. In 2011, the Center for

Disease Control estimate 80,000 invasive MRSA infections and 11,285 related deaths in the United States [3]. These deaths are primarily due to MRSA strains that are resistant to macrolides, monovalent cationic antimicrobials, quinolones, bivalent quaternary ammonium compounds, tetracycline, and all beta-lactam antibiotics including penicillin, amoxicillin, methicillin, and oxacillin [4]. Inactivation of antibiotics, reduction in cellular permeability, alteration of antibiotic target sites, and bacterial efflux pumps convey drug resistance [5]. Several multidrug efflux genes, such as the NorA, NorB, and NorC from the *S. aureus* chromosome, confer resistance to quinolones and other antibiotics [6, 7]. Disturbingly, an increase in the variety of drug-resistant strains of

S. aureus has been noted in the past years, with the most prevalent being vancomycin-resistant *S. aureus* (VRSA). Usually VRSA develops in MRSA patients treated with vancomycin, the frontline treatment to MRSA. While VRSA is rare with most *S. aureus* being vancomycin-intermediate meaning that large amounts of vancomycin still kill the organisms, this presents a new challenge to combat *S. aureus* infections. These superbugs are generally sensitive to intravenous medication, such as quinupristin-

dalfopristin, that require slow infusion in a large fluid volume, making it unrealistic for administration to CA-MRSA patients in an outpatient setting. Quinupristin-dalfopristin can also cause disabling myopathy as a side effect. Due to documented increases of a global spread of CA-MRSA in just the past 20 years and the increases in antibiotic resistances, there is a need for new treatment options [2].




Figure 1: Experimental Overview. Protein sequences for three *E. coli* MFS proteins underwent PSI-BLAST. Hypothetical protein homologs meeting five parameters are likely functional MFS and then compared to homologs of predicted function.

Most multidrug resistance efflux pumps eject various substrates regardless of structure, a common feature of the Major Facilitator Superfamily (MFS) they belong to [8]. In bacteria, about 25% of characterized membrane transport proteins come from the MFS [9]. This group of transporters contains 74 families that move a wide variety of substrates including sugar phosphates, nucleosides, ions, amino acids, peptides, and drugs across the cytoplasmic membrane [10]. X-ray crystallography established *E. coli*'s structure of three members of this conserved protein family: glycerol-3-phosphate transporter (GlpT), lactose permease (LacY), and multidrug transporter (EmrD). These structures, listed in the PDB as 1PW4, 1PV7, and 2GFP for GlpT, LacY, and EmrD, respectively, demonstrate that MFS proteins function via the substrate's electrochemical potential. MFS proteins are usually 400 to 600 amino acids long, with most containing 11 to 14 transmembrane alpha helices connected by hydrophilic loops [10].

Hypothetical proteins make up approximately 50% of reference strain *S. aureus* NCTC 8325 genome [11]. Nucleic acid sequence only predicts hypothetical proteins [12]. There is no experimental evidence for a hypothetical protein's function exists; ergo a hypothetical protein may not actually be functional. Further, some hypothetical proteins do not follow conventional phylogenetic lineage. Usually the two groups of hypothetical proteins are uncharacterized protein families and domains of unknown function, or experimentally identified proteins with structural domains that do not relate to already established functions. However, databases frequently label a protein hypothetical if it comes from a newly deposited sequence and no annotation was available for it at that time [13]. This is likely the case with *S. aureus* NCTC 8325, whose genome was published in 2006 [14].

With approximately half of all *S. aureus* NCTC 8325 genomic protein sequences currently annotated as hypothetical proteins and 25% of all membrane transport proteins belonging to the MFS, ergo likely related to antibiotic resistance, there is great potential for the discovery of new drug targets here [15]. Since proper annotation of hypothetical proteins can lead to new therapeutic targets, a high demand to characterize hypothetical proteins is present. Ergo, this study uses *in silico* techniques to identify and characterize hypothetical proteins in *S. aureus* NCTC 8325 that are related to the protein MFS.

Methodology:

Figure 1 illustrates the overall experimental design. To identify MFS-related hypothetical proteins, protein sequences for the three *E. coli* MFS crystal structures, 1PW4 (GlpT), 1PV7 (LacY), and 2GFP (EmrD), were downloaded from PDB. A Position-Specific Iterative Basic Local Alignment Search Tool (PSI-BLAST) revealed proteins of interest when searched with each sequence against the *S. aureus* NCTC 8325 genome. If the protein was hypothetical, it underwent

protein-protein BLAST (BLASTP) against NCBI's entire non-redundant protein database to identify top matching homologs in any species. NCBI provides both BLAST algorithms.

Table 1: Homologs in *S. aureus* NCTC 8325 to GlpT from *E. coli*

Protein	Accession	QC %	%ID
glycerol-3-phosphate transporter	WP_001010111.1	97	57
antiporter	WP_001008722.1	96	32
glucuronate transporter	WP_000660709.1	90	22
quinolone resistance protein NorB	WP_000381270.1	21	28
multidrug efflux MFS transporter NorA	WP_001041272.1	15	27
MFS transporter	WP_001154220.1	27	20
probable glycolipid permease LtaA	Q2FZP8.2	27	20
conserved hypothetical protein	ABD31816.1	7	27
hypothetical protein SAOUHSC_00058	YP_498663.1	56	23
hypothetical protein SAOUHSC_00078	YP_498678.1	50	22
hypothetical protein SAOUHSC_00952	YP_499505.1	41	20
hypothetical protein SAOUHSC_02620	WP_000436818.1	4	45

QC, Query Cover; %ID, percentage of identity; MFS, major facilitator superfamily

Physicochemical Characterization

To characterize the proteins, the ExPasy ProtParam server computed several physicochemical characterizations. The number of amino acids, molecular weight, total number of charged residues (the addition of arginine and lysine for negatively charged and aspartic acid added to glutamic acid for positively charged) [16]. The algorithm determines the theoretical isoelectric point, the pH where a molecule carries no net electrical charge, from the number of charged residues. Further, the program calculates the extinction coefficient, the amount of light absorbed by the protein at a 280nm wavelength, which is helpful for protein purification procedures [17]. A protein's stability in a test tube under physiological conditions is measured by its instability index [18]. The relative volume occupied by open side chain amino acids in a protein is the aliphatic index [19]. The grand average hydropathy (GRAVY) is the total of the hydropathy values of all amino acids in the protein divided by the number of residues a measure of hydrophobicity for a given molecule [20]. The SOSUI server also determines a protein's hydrophobicity, though via solubility computations, and it further characterizes potential transmembrane regions [21].

Domain Identification

Both Pfam and the conserved domain database (CDD) identified domains. The Pfam database is a collection of protein families represented by hidden Markov models and multiple sequence alignments [22, 23]. Conserved domain database BLAST (CDD-BLAST) uses a variant of PSI-BLAST to scan a set of pre-calculated position-specific scoring matrices from a protein query [24]. Researchers frequently use Pfam and CDD-BLAST together to examine protein domains to predict function prior to modeling the protein to evaluate its binding capability [15, 25].

Protein relatedness

Hypothetical proteins between 300 and 700 amino acids long with well-defined BLASTP homologs, CD06174 MFS domain identified by CDD-BLAST, and an MFS domain found by Pfam under went evolutionary analyses against non-redundant defined homologs identified from prior PSI-BLAST and BLASTP searches. Two programs, PROMALS3D and CLUSTALW, did multiple sequence alignment. PROMALS3D aligned each set of proteins based on homology to the E. coli protein with the established structure by constructing alignments using information from available homologs with 3D structures, sequence database searches, and secondary structure prediction [26]. CLUSTALW aligned all protein sequences together as one large dataset [27]. The PHYLIP package ProtDist program used the output from CLUSTALW to produce a distance matrix using default settings such as the Jones-Taylor-Thornton distance model [28]. Another program in

the PHYLIP suite, Neighbor, used this matrix to construct a neighbor joining and unweighted pair group method with arithmetic mean trees. Again as verification, another phylogenetic tree building approach, the Fitch-Margoliash and Least-Squares Distance method, verified the results. DrawTree from the PHYLIP suite illustrated phylogenetic trees produced. All analyses used default settings.

Discussion:

This study aimed to identify and characterize hypothetical proteins in S. aureus NCTC 8325 that belong to the MFS of proteins. Three E. coli MFS proteins with established structure (GlpT, LacY, and EmrD) underwent PSI-BLAST against the S. aureus NCTC 8325 genome to identify homologs. Tables 1 to 3 list homologs for GlpT, LacY, and EmrD, respectively. This method identified eleven hypothetical proteins. Researchers need further examination to determine if these hypothetical proteins belong to the MFS.




Figure 2: Alignment of GlpT homologs aligned by PROMALS3D. Magenta names are representative sequences colored red to identify predicted alpha-helix secondary structures. The black names belonging to the same alignment group as the magenta name above it, indicating a strong relationship between the two. Consensus_aa, consensus amino acid sequence; Consensus_ss, consensus predicted secondary structures; h, consensus predicted secondary structure alpha-helix.



Table 2: Homologs in *S. aureus* NCTC 8325 to LacY from *E. coli*

Protein	Accession	QC %	%ID
multidrug efflux MFS transporter NorA	WP_001041272.1	45	28
hydroxyethylthiazole kinase	WP_000610051.1	17	25
siderophore biosynthesis protein SbnD	WP_000610051.1	17	25
MFS transporter	WP_000610884.1	35	27
glucarate transporter	WP_000660709.1	46	29
proline/betaine transporter	WP_000347061.1	14	27
nitrate transporter NarT	WP_000278558.1	17	32
nickel ABC transporter permease	WP_000584765.1	19	34
antibiotic MFS transporter	WP_000675401.1	11	29
hypothetical protein SAOUHSC_02866	YP_501322.1	12	31
hypothetical protein SAOUHSC_02307	YP_500786.1	23	23
hypothetical protein SAOUHSC_02309	WP_001287088.1	11	31

QC, Query Cover; %ID, percentage of identity; MFS, major facilitator super-family

To distinguish that, homolog identification, physiochemical characterization, transmembrane enumeration, and domain identification compared hypothetical proteins to established MFS proteins. **Table 4** lists the top BLASTP homolog for each hypothetical protein regardless of origin. A hypothetical protein that has a homolog with a well-defined function is more likely related. SAOUHSC_02307, SAOUHSC_02309, and ABD31816.1 hit several general membrane proteins. SAOUHSC_02620 and SAOUHSC_02866 matched several hypothetical proteins as well as general membrane proteins. This indicates these hypothetical proteins may not be in the MFS.




Figure 3: Alignment of EmrD homologs aligned by PROMALS3D. Magenta names are representative sequences colored red to identify predicted alpha-helix secondary structures. The black names belonging to the same alignment group as the magenta name above it, indicating a strong relationship between the two. Consensus_aa, consensus amino acid sequence; Consensus_ss, consensus predicted secondary structures; h, consensus predicted secondary structure alpha-helix.

Table 3: Homologs in *S. aureus* NCTC 8325 to EmrD from *E. coli*

Protein	Accession	QC %	%ID
Bcr/CfIA family drug resistance efflux transporter	WP_000999131.1	62	25
drug:proton antiporter	WP_000038961.1	42	27
multidrug MFS transporter	WP_001820335.1	40	26
nitrate transporter NarT	WP_000278558.1	52	24
multidrug efflux MFS transporter NorA	WP_001041272.1	84	20
chloramphenicol resistance protein DHAI	WP_000026194.1	41	20
quinolone resistance protein NorB	WP_001066546.1	34	23
conserved hypothetical protein	ABD31642.1	62	25
hypothetical protein SAOUHSC_02435	YP_500904.1	34	22
hypothetical protein SAOUHSC_02752	YP_501211.1	51	20

Table 4: Homologs to hypothetical proteins

Hypothetical Protein	Top Match
SAOUHSC_00058	quinolone resistance protein NorB
SAOUHSC_00078	siderophore biosynthesis protein SbnD
SAOUHSC_00952	glycolipid permease LtaA
SAOUHSC_02307	putative membrane spanning protein
SAOUHSC_02309	membrane protein
SAOUHSC_02435	macrolide MFS transporter
SAOUHSC_02620	membrane protein
SAOUHSC_02752	chloramphenicol resistance protein DHAI
SAOUHSC_02866	membrane protein
ABD31816.1	membrane protein
ABD31642.1	Bcr/CfIA family drug resistance efflux transporter

QC, Query Cover; %ID, percentage of identity; MFS, major facilitator super-family

MFS, major facilitator super-family

Table 5: Physicochemical properties

Protein	# AA	MW	pI	# neg	# pos	EC	II	AI	GRAVY
GlpT	451	50204.2	8.69	28	33	115660	36.12	99.73	0.505
LacY	417	46457.1	9.02	17	24	54240	29.54	109.93	0.906
EmrD	375	39995.1	9.10	12	18	61800	37.90	121.23	0.942
SAOUHSC_00058	462	48999.6	9.49	17	29	59610	22.37	128.74	0.948
SAOUHSC_00078	418	44835.3	9.54	13	27	53570	46.13	120.65	0.786
SAOUHSC_00952	402	45457.6	9.54	16	26	63830	36.90	128.28	0.936
SAOUHSC_02307	163	19404.9	9.62	16	22	32430	48.51	123.80	0.134
SAOUHSC_02309	159	18972.3	9.18	13	18	38850	36.78	108.43	0.140
SAOUHSC_02435	397	44337.3	9.44	16	31	47830	24.38	127.68	0.868
SAOUHSC_02620	215	24956.7	6.10	16	15	34630	56.72	111.91	0.573
SAOUHSC_02752	375	40245.1	9.68	12	20	43430	29.41	132.51	0.918
SAOUHSC_02866	822	90409.3	6.46	90	86	58790	31.15	107.93	0.159
ABD31816.1	416	47645.0	9.19	31	43	39810	26.46	107.62	0.282
ABD31642.1	312	34467.5	10.05	11	20	34950	28.19	125.61	0.897

AA, number of amino acids; MW, molecular weight; pI, theoretical isoelectric point; # neg, total number of negatively charged residues (Asp + Glu); # pos, total number of positively charged residues (Arg + Lys); EC, extinction coefficient assuming all pairs of Cys residues form cystines; II, instability index; AI, aliphatic index; GRAVY, grand average hydropathy.

Table 6: Transmembrane Regions Identified by SOSUI

Locus Tag	Number	Base-Pair Position
GlpT	10	26 - 43, 102 - 124, 160 - 181, 187 - 208, 251 - 273, 290 - 312, 320 - 342, 350 - 372, 384 - 406, 414 - 435
LacY	12	11 - 33, 44 - 66, 75 - 97, 106 - 128, 144 - 166, 174 - 196, 215 - 237, 260 - 282, 288 - 310, 313 - 335, 346 - 368, 379 - 401
EmrD	10	4 - 26, 32 - 54, 69 - 91, 127 - 149, 153 - 175, 205 - 227, 235 - 256, 263 - 285, 291 - 313, 346 - 368
SAOUHSC_00058	13	12 - 34, 45 - 67, 88 - 110, 134 - 156, 163 - 184, 198 - 220, 226 - 247, 262 - 284, 301 - 323, 330 - 349, 355 - 373, 403 - 425, 431 - 453
SAOUHSC_00078	12	11 - 33, 45 - 67, 80 - 102, 104 - 126, 145 - 167, 171 - 192, 224 - 246, 256 - 277, 291 - 313, 317 - 339, 351 - 371, 376 - 398
SAOUHSC_00952	11	15 - 37, 42 - 64, 85 - 107, 113 - 134, 144 - 166, 173 - 195, 218 - 240, 251 - 273, 280 - 302, 307 - 329, 374 - 396
SAOUHSC_02307	2	17 - 39, 50 - 72
SAOUHSC_02309	2	20 - 42, 48 - 70
SAOUHSC_02435	11	5 - 27, 36 - 58, 66 - 88, 92 - 114, 133 - 155, 162 - 184, 212 - 234, 248 - 270, 286 - 308, 333 - 355, 361 - 382
SAOUHSC_02620	4	38 - 60, 73 - 95, 108 - 130, 143 - 165
SAOUHSC_02752	8	12 - 34, 53 - 75, 80 - 101, 110 - 132, 139 - 161, 193 - 215, 224 - 246, 260 - 282
SAOUHSC_02866	12	10 - 32, 170 - 192, 198 - 220, 225 - 246, 267 - 289, 303 - 324, 348 - 370, 510 - 532, 538 - 560, 579 - 601, 624 - 646, 655 - 677
ABD31816.1	6	75 - 97, 119 - 141, 143 - 165, 169 - 191, 195 - 216, 389 - 411
ABD31642.1	9	13 - 35, 53 - 74, 80 - 102, 107 - 129, 138 - 160, 167 - 189, 221 - 243, 254 - 276, 285 - 307




Figure 4: Representative phylogenetic tree of proteins produced via PHYLIP package programs showing six hypothetical proteins belong evolutionarily to the major facilitator superfamily (MFS). SAOUHSC_00058, SAOUHSC_02435, SAOUHSC_02752 and ABD31642.1 are related to drug efflux proteins. SAOUHSC_00078 is closely related to a siderophore biosynthesis protein as SAOUHSC_00952 is confirmed to be a glycolipid permease.

Table 5 lists the physiochemical parameters calculated by ExPASy. Since MFS proteins are usually 400 to 600 amino acids, any hypothetical protein outside the 300 to 700 amino acid range is unlikely to be functional. Four of the five hypothetical proteins that had ambiguous membrane protein BLASTP hits, SAOUHSC_02307, SAOUHSC_02309, SAOUHSC_02620, and SAOUHSC_02866, came up outside this size range. Examination of other physiochemical calculations failed to be consistent in predicting MFS proteins among hypotheticals though some proteins outside this size range had varied theoretical index (SAOUHSC_02620 and SAOUHSC_02866) and GRAVY values (<0.05 for SAOUHSC_02307, SAOUHSC_02309, SAOUHSC_02866, and ABD31816.1) compared to proteins with expected size. This

indicates that these specific hypothetical proteins may not be in the MFS.

SOSUI calculates the average hydrophobicity of a protein. If hydrophobicity exists, the server labels that portion of the protein as a transmembrane region. Table 6 details transmembrane regions as described by the SOSUI server. MFS proteins typically have 11 to 13 transmembrane regions, so SAOUHSC_02307, SAOUHSC_02309, SAOUHSC_02620, and ABD31816.1 are unlikely functioning MFS proteins because they have half or less of the necessary number of transmembrane regions. Since GlpT and LacY had 10 transmembrane regions per SOSUI (data not shown), it is still possible that SAOUHSC_02752 and ABD31642.1 are related to MFS proteins based on this analysis.

Table 7: CDD-BLAST domain data

Hypothetical Protein	Domains
GlpT	cd06174 PRK11273
LacY	cd06174 pfam01306
EmrD	cd06174 PRK11652
SAOUHSC_00058	cd06174 pfam07690
SAOUHSC_00078	cd06174 PRK09874
SAOUHSC_00952	cd06174 pfam07690
SAOUHSC_02307	COG3402
SAOUHSC_02309	cl01348
SAOUHSC_02435	cd06174 TIGR00900
SAOUHSC_02620	COG3152
SAOUHSC_02752	cd06174 COG2814
SAOUHSC_02866	pfam03176 cl21543 COG2409
ABD31816.1	COG1289
ABD31642.1	cd06174

cd06174 and pfam07690, Major Facilitator Superfamily; PRK11273, glycerol-3-phosphate transporter; pfam01306, LacY proton/sugar symporter; PRK11652, multidrug resistance protein D; PRK09874, drug efflux system protein MdtG; COG3402, YdbS; cl01348, bPH_2 super family; TIGR00900, H⁺ Antipporter protein; COG3152, yhaH; COG2814, arabinose efflux permease; pfam03176 and cl21543, MMPL super family; COG2409, YdfJ; COG1289, YccC.

Finally, potential MFS hypothetical proteins should have similar domains to those found in GlpT, LacY, and EmrD. **Table 7** lists the CDD-BLAST results and **Table 8** the Pfam results for domain identification. Most hypothetical proteins with the appropriate size and well-defined PSI-BLAST homologs had the CD06174 MFS domain identified by CDD-BLAST and the MFS_1 domain identified by Pfam. GlpT and EmrD have these domains too.

Based on these data collectively, the following hypothetical proteins are likely MFS proteins due to their size (300 - 700 amino acids), well-defined BLAST homologs (no generalized membrane or hypothetical proteins), more than seven transmembrane regions, and CD06174 and MFS domains from CDD-BLAST and Pfam, respectively, underwent evolutionary analyses: SAOUHSC_00058, SAOUHSC_00078, SAOUHSC_00952, SAOUHSC_02435, SAOUHSC_02752, and ABD31642.1. Since either the GlpT or EmrD proteins identified the six hypothetical proteins most likely to belong to the MFS, the study removed LacY and its homologs in **Table 2** from further study.

Table 8: Pfam domain data

Hypothetical Protein	Domains
GlpT	MFS_1
LacY	LacY_symp
EmrD	MFS_1
SAOUHSC_00058	MFS_1
SAOUHSC_00078	MFS_1
	sugar_tr
SAOUHSC_00952	MFS_1
SAOUHSC_02307	bPH_2
SAOUHSC_02309	No Pfam-A matches
SAOUHSC_02435	MFS_3
SAOUHSC_02620	DUF805
SAOUHSC_02752	MFS_1
SAOUHSC_02866	MMPL family
ABD31816.1	No Pfam-A matches
ABD31642.1	MFS_1

MFS_1, Major Facilitator Superfamily; LacY_symp, LacY proton/sugar symporter; sugar_tr, sugar and other transporter; bPH_2, bacterial Pleckstrin homology domain; MFS_3, Transmembrane secretion effector; DUF805, Protein of unknown function; MMPL family, putative integral membrane proteins.

To evaluate how related these hypothetical proteins were, proteins of interest underwent multiple sequence alignment and phylogenetic tree construction. For these analyses, all defined homologs from **Tables 1 and 3** combined with hypothetical proteins fitting the study's criteria completed multiple sequence alignment as displayed in **Figures 2 and 3**, respectively. These analyses included top BLASTP hits from **Table 4** not already included in **Tables 1 and 3**. Both alignments found over 10 alpha helices in the consensus sequences, as expected from MFS members. Hypothetical proteins aligned with their top BLASTP hits from **Table 4** best, with SAOUHSC_00952 also closely aligning with the MFS transporter. To visualize how closely related these proteins are phylogenetic trees were constructed. Though all similar, a representative tree of all the proteins and their homologs is shown in **Figure 4**. The same NorA multidrug efflux MFS transporter came up in all three *E. coli* PSI-BLASTs while GlpT (1PW4) and EmrD (3GFP) identified two separate NorB quinolone resistance proteins. SAOUHSC_00058 nuzzled between the two NorB proteins. As expected, phylogeny confirmed the multiple sequence alignment. Hypothetical proteins related closely with their top PSI-BLAST hits from **Table 4**, with SAOUHSC_00952 being closely related to the MFS transporter also. Floyd's illustration of the established proteins shown in the phylogenetic tree presented here is similarly arranged [**4**].

Conclusion:

This study identified eleven hypothetical proteins homologous to *E. coli* MFS proteins with known structure. Six of those hypothetical proteins, SAOUHSC_00058, SAOUHSC_00078, SAOUHSC_00952, SAOUHSC_02435, SAOUHSC_02752, and ABD31642.1, were between 300 and 700 amino acids, had well-defined BLASTP homologs, over seven transmembrane regions, CD06174 domain from CDD-BLAST, and an MFS domain from Pfam. Based on these results alongside multiple sequence alignment and phylogenetic trees, SAOUHSC_00058 is likely a quinolone resistance protein (NorB) due to its close relation to two NorB proteins identified by either GlpT or EmrD. SAOUHSC_00058 may be a siderophore biosynthesis protein (SbnD). SAOUHSC_00952, a glycolipid permease (LtaA), and another MFS transporter closely are related. Further, UniProt has SAOUHSC_00952 labeled as a glycolipid permease LtaA with experimental evidence at the protein level, unlike all the other hypothetical proteins studied here labeled as uncharacterized [29]. SAOUHSC_02435 hits a macrolide MFS transporter while SAOUHSC_02752 matches a chloramphenicol resistance (DHA1), and ABD31642.1 may be a Bcr/CflA family drug resistance efflux transporter. These data manually verifies the *in silico* identity of six hypothetical proteins from reference strain *S. aureus* NCTC 8325 in public databases.

References:

- [1] Holden MT *et al.* *Proc. Natl. Acad. Sci. U. S. A.* 2004 **101**:26 [PMID: 15213324].
- [2] Stinear TP *et al.* *Genome Biol Evol* 2014 **6**:2 [PMID: 24482534].
- [3] http://www.cdc.gov/drugresistance/pdf/carb_national_strategy.pdf
- [4] Floyd JL *et al.* *Antimicrob Agents Chemother* 2010 **54**:12 [PMID: 20855745].
- [5] Nikaido H. *Annu Rev Biochem* 2009 **78** [PMID: 19231985].
- [6] Fournier B *et al.* *J Bacteriol* 2000 **182**:3 [PMID: 10633099].
- [7] Ding Y *et al.* *J Bacteriol* 2008 **190**:21 [PMID: 18723624].
- [8] Pao SS *et al.* *Microbiol Mol Biol Rev* 1998 **62**:1 [PMID: 9529885].
- [9] Law CJ *et al.* *Annu Rev Microbiol* 2008 **62** [PMID: 18537473].
- [10] Reddy VS *et al.* *FEBS J* 2012 **279**:11 [PMID: 22458847].
- [11] School K *et al.* *Bioinformatics* 2016 **12**: 3.
- [12] Bharat Siva Varma P *et al.* *J Infect Public Health* 2015 **8**:6 [PMID: 26025048].
- [13] Ijaq J *et al.* *Front Genet* 2015 **6**:119 [PMID: 25873935].
- [14] Gillaspay AF *et al.* (2006) The *Staphylococcus aureus* NCTC 8325 genome. In: Fischetti VA, Novick RP, Ferretti JJ, Portnoy DA, Rood JI, editors. *Gram-positive pathogens*, 2nd ed. Washington (DC): ASM Press. p. 381–412.
- [15] Islam MS *et al.* *Genomics Inform* 2015 **13**:2 [PMID: 26175663].
- [16] Wilkins MR *et al.* *Methods Mol Biol* 1999 **112** [PMID: 10027275].
- [17] Gill SC & von Hippel PH. *Anal Biochem* 1989 **182**:2 [PMID: 2610349].
- [18] Guruprasad K *et al.* *Protein Eng* 1990 **4**:2 [PMID: 2075190].
- [19] Ikai AJ. *J Biochem* 1980 **88**:6 [PMID: 7462208].
- [20] Kyte J & Doolittle RF. *J Mol Biol* 1982 **157**:1 [PMID: 7108955].
- [21] Hirokawa T *et al.* *Bioinformatics* 1998 **14**:4 [PMID: 9632836].
- [22] Sonnhammer E *et al.* *Proteins* 1997 **28**:3 [PMID: 9223186].
- [23] Finn RD *et al.* *Nucleic Acids Res* 2006 **34**:D247-D51 [PMID: 16381856].
- [24] Marchler-Bauer A *et al.* *Nucleic Acids Res* 2015 **43**:D222-6 [PMID: 25414356].
- [25] Mohan R & Venugopal S. *Bioinformatics* 2012 **8**:15 [PMID: 23055618].
- [26] Pei J *et al.* *Nucleic Acids Res* 2008 **36**:7 [PMID: 18287115].
- [27] Thompson JD *et al.* *Nucleic Acids Res* 1994 **22**:22 [PMID: 7984417].
- [28] Felsenstein J. (1989). PHYLIP-phylogeny inference package (version 3.2). *Cladistics*, 5, 163-166.
- [29] Gründling A & Schneewind O. *Journal of bacteriology* 2007 **189**:6 [PMID: 17209021].

Edited by P Kanguane

Citation: Marklevitz & Harris, *Bioinformatics* 12(4): 254-262 (2016)

License statement: This is an Open Access article which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. This is distributed under the terms of the Creative Commons Attribution License